ALMS
ALUMIS INC.
NASDAQ · Healthcare · Biotechnology · US
$9.18
−7.27%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
Market Cap
$1.19B
MomentumView details →
1D Return
−7.27%
YTD Return
−4.82%
RSI (14)
21.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
Market Cap
$1.19B
RSI (14)
21.3
MomentumView details →
1D Return
−7.27%
YTD Return
−4.82%
SummaryUpdated Jun 1, 2026
Alumis Inc. (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California. Originally incorporated as Esker Therapeutics, Inc., the company rebranded to Alumis Inc. in January 2022 before going public in February 2021. The company focuses on developing innovative medicines for autoimmune and inflammatory disorders, with its lead programs targeting a specific enzyme pathway called tyrosine kinase 2 (TYK2) that plays a crucial role in immune system regulation.
Similar companies
Latest newsMore news →
ALUMIS stock resumed trading and plunged 57% in premarket after a failed trial sale.10d agoAlumis announced that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus did not meet primary and secondary endpoints in the overall population, but showed robust responses in the IFNGS-high subgroup, supporting Phase 3 development in SLE.10d agoAlumis announced topline results from its ONWARD3 long-term extension study, showing envudeucitinib achieved high skin clearance rates in psoriasis patients.32d ago